The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Prognostic and Predictive Biomarkers in Gliomas
Open accessAbstract
Gliomas are the most common central nervous system tumors. New technologies, including genetic research and advanced statistical methods, revolutionize the therapeutic approach to the patient and reveal new points of treatment options. Moreover, the 2021 World Health Organization Classification of Tumors of the Central Nervous System has fundamentally changed the classification of gliomas and incorporated many molecular biomarkers. Given the rapid progress in neuro-oncology, here we compile the latest research on prognostic and predictive biomarkers in gliomas. In adult patients, IDH mutations are positive prognostic markers and have the greatest prognostic significance. However, CDKN2A deletion, in IDH-mutant astrocytomas, is a marker of the highest malignancy grade. Moreover, the presence of TERT promoter mutations, EGFR alterations, or a combination of chromosome 7 gain and 10 loss upgrade IDH-wildtype astrocytoma to glioblastoma. In pediatric patients, H3F3A alterations are the most important markers which predict the worse outcome. MGMT promoter methylation has the greatest clinical significance in predicting responses to temozolomide (TMZ). Conversely, mismatch repair defects cause hypermutation phenotype predicting poor response to TMZ. Finally, we discussed liquid biopsies, which are promising diagnostic, prognostic, and predictive techniques, but further work is needed to implement these novel technologies in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–248 of 248
TERT mutation in glioma: Frequency, prognosis and risk
Yang, Y., Chen, Q., Maling, G., Xiang, W., Yanhui, L., Ruofei, L., Yunhe, M., Jiewen, L., & Mao, Q. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.05.066 · Cited by 57
Zhu, P., & Zhu, J. (2017) · Chinese Clinical Oncology · doi:10.21037/cco.2017.06.29 · Cited by 57
Molecular subtyping reveals immune alterations in IDH wild‐type lower‐grade diffuse glioma
Wu, F., Li, G., Liu, H., Zhao, Z., Chai, R., Liu, Y., Jiang, H., Zhai, Y., Feng, Y., Li, R., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5468 · Cited by 57
Jiang, H., Ren, X., Cui, X., Wang, J., Jia, W., Zhou, Z., & Lin, S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not027 · Cited by 53
Vuong, H. G., Nguyen, T. Q., Ngo, T. N. M., Nguyen, H. C., Fung, K., & Dunn, I. F. (2020) · BMC Cancer · doi:10.1186/s12885-020-07364-5 · Cited by 52
Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas
Zhao, Z., Zhang, C., Li, M., Shen, Y., Feng, S., Liu, J., Li, F., Hou, L., Chen, Z., Jiang, J., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz156 · Cited by 50
Cai, J., Zhang, J., Wu, P., Yang, W., Ye, Q., Chen, Q., & Jiang, C. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2951-0 · Cited by 49
Zhang, I., Beus, M., Stochaj, U., Le, P. U., Zorc, B., Rajić, Z., Petrecca, K., & Maysinger, D. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0103-0 · Cited by 49
Chistiakov, D. A., & Chekhonin, V. P. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.07.007 · Cited by 48
The Role of Circulating MicroRNA in Glioblastoma Liquid Biopsy
Garcia, C. M., & Toms, S. A. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.03.128 · Cited by 48
Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors
Chamberlain, M. C., & Born, D. E. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1906-y · Cited by 47
von Bueren, A. O., Bacolod, M. D., Hagel, C., Heinimann, K., Fedier, A., Kordes, U., Pietsch, T., Köster, J., Grotzer, M. A., Friedman, H. S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.403 · Cited by 46
Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer
Bauml, J. M., & Levy, B. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0969 · Cited by 46
Circulating miR‐26a and miR‐21 as biomarkers for glioblastoma multiform
ParvizHamidi, M., Haddad, G., Ostadrahimi, S., Ostadrahimi, N., Sadeghi, S., Fayaz, S., & Fard‐Esfahani, P. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1707 · Cited by 45
Prognostic role of microRNA-21 expression in gliomas: a meta-analysis
Li, C., Sun, J., Xiang, Q., Liang, Y., Zhao, N., Zhang, Z., Liu, Q., & Cui, Y. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2233-7 · Cited by 44
Zhao, Y., Wang, X., Cao, C., Weng, H., Xu, C., Li, K., Li, J.-L., Lan, J. Q., Zeng, X., & Li, Z. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00127 · Cited by 43
Wang, L., Yu, J., Xu, J., Zheng, C., Li, X., & Du, J. (2014) · Gene · doi:10.1016/j.gene.2014.10.032 · Cited by 42
Yin, A., Zhang, L., Cheng, J., Dong, Y. H., Liu, B.-L., Han, N., & Zhang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085102 · Cited by 42
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas
Alentorn, A., Dehais, C., Ducray, F., Carpentier, C., Mokhtari, K., Figarella-Branger, D. F., Chinot, O. L., Moyal, E. C., Ramirez, C., Loiseau, H., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002014 · Cited by 42
Glioblastoma Circulating Cells: Reality, Trap or Illusion?
Lombard, A., Goffart, N., & Rogister, B. (2015) · Stem Cells International · doi:10.1155/2015/182985 · Cited by 39
Abbas, M. N., Kausar, S., Wang, F., Zhao, Y., & Cui, H. (2019) · Cells · doi:10.3390/cells8040350 · Cited by 39
Nørøxe, D. S., Østrup, O., Yde, C. W., Ahlborn, L. B., Nielsen, F. C., Michaelsen, S. R., Larsen, V. A., Skjøth‐Rasmussen, J., Brennum, J., Hamerlik, P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27030 · Cited by 38
Wu, C., Su, J., Long, W., Qin, C., Wang, X., Xiao, K., Yang, L., Xiao, Q., Wang, J., Pan, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15846 · Cited by 38
Ghasimi, S., Wibom, C., Dahlin, A. M., Brännström, T., Golovleva, I., Andersson, U., & Melin, B. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2066-4 · Cited by 36
Circulating microRNA-137 is a potential biomarker for human glioblastoma.
Hy, L., Li, Y., Li, Y., Xw, S., & Chen, H. (2016) · PubMed · Cited by 36
Bale, T., Jordan, J. T., Rapalino, O., Ramamurthy, N., Jessop, N. A., DeWitt, J. C., Nardi, V., Martinez‐Lage, M., Frosch, M. P., Batchelor, T. T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy201 · Cited by 35
Lewandowska, M. A., Furtak, J., Szylberg, T., Roszkowski, K., Windorbska, W., Rytlewska, J., & Jóźwicki, W. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0050-7 · Cited by 33
Self-citationJiang, G., Mu, J., Liu, X., Peng, X., Zhong, F., Yuan, W., Deng, F., Peng, X., Peng, S., & Zeng, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-61155-3 · Cited by 33
Prognostic Significance of MicroRNAs in Glioma: A Systematic Review and Meta-Analysis
Zhang, Y., Chen, J., Xue, Q., Wang, J., Zhao, L., Han, K., Zhang, D., & Hou, L. (2019) · BioMed Research International · doi:10.1155/2019/4015969 · Cited by 32
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.551160 · Cited by 31
Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
Bagley, S. J., Till, J. E., Abdalla, A., Sangha, H. K., Yee, S. S., Freedman, J. M., Black, T. A., Hussain, J., Binder, Z. A., Brem, S. S., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab011 · Cited by 30
Roth, J. J., Fierst, T. M., Waanders, A. J., Yimei, L., Biegel, J. A., & Santi, M. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw001 · Cited by 29
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
Caccese, M., Ius, T., Simonelli, M., Fassan, M., Cesselli, D., Dipasquale, A., Cavallin, F., Padovan, M., Salvalaggio, A., Gardiman, M. P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186716 · Cited by 28
Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis
Wang, J., Che, F., & Zhang, J. (2019) · The International Journal of Biological Markers · doi:10.1177/1724600819840033 · Cited by 23
Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions
Roszkowski, K., Furtak, J., Żurawski, B. A., Szylberg, T., & Lewandowska, M. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111876 · Cited by 21
Self-citationLi, J.-H., He, Z., Lin, F., Chen, Z., Yang, S.-Y., Duan, H., Jiang, X., Al-Nahari, F., Zhang, X., Wang, J.-H., et al. (2019) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2019.06.001 · Cited by 20
Møllersen, K., Zortea, M., Schopf, T. R., Kirchesch, H. M., & Godtliebsen, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190112 · Cited by 18
Duque, M., Pinheiro, K. D. V., Thomaz, A., da Silva, C. A., Freire, N. H., Brunetto, A. T., Schwartsmann, G., Jaeger, M. D. C., de Farias, C. B., & Roesler, R. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01280-5 · Cited by 17
Meng, W., Jiang, Y., & Ma, J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s140447 · Cited by 16
Prognostic role of microRNA-155 expression in gliomas: A meta-analysis
Zhou, Y., Wang, X., Liu, Z., Huang, X., Li, X., Cheng, K., & Jiang, X. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.12.005 · Cited by 15
Azam, Z., Quillien, V., Wang, G., & To, S.-S. T. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1551621 · Cited by 15
MN1overexpression with varying tumor grade is a promising predictor of survival of glioma patients
Saini, M., Jha, A. N., Tangri, R., Qudratullah, M., & Ali, S. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa231 · Cited by 14
Dai, Y., Ning, X., Han, G., & Li, W. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9104-7 · Cited by 13
Richard, S., Tachon, G., Milin, S., Wager, M., & Karayan, L. (2020) · Cancer Medicine · doi:10.1002/cam4.3217 · Cited by 13
Lee, K., Koo, H., Kim, Y., Kim, D., Son, E., Yang, H., Lim, Y., Hur, M., Lee, H. W., Choi, S. W., et al. (2020) · Cancers · doi:10.3390/cancers12113210 · Cited by 13
Targeting EGFR in glioblastoma with a novel brain-penetrant small molecule EGFR-TKIPreprint
Ni, J., Yang, Y., Wang, Q., Bergholz, J. S., Jiang, T., Roberts, T. M., Gray, N. S., & Zhao, J. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426030 · Cited by 10
Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta‐analysis
Song, Y., Zhang, J., He, M., & Xu, J. (2020) · BioMed Research International · doi:10.1155/2020/4689689 · Cited by 6
High expression of microRNA 221 is a poor predictor for glioma
Song, Y., He, M., Zhang, J., & Xu, J. (2020) · Medicine · doi:10.1097/md.0000000000023163 · Cited by 6
Cited by
Khalighi, S., Reddy, K., Midya, A., Pandav, K. B., Madabhushi, A., & Abedalthagafi, M. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00575-0 · Cited by 306
Bian, Z., Fan, R., & Xie, L. (2022) · Genes · doi:10.3390/genes13050851 · Cited by 302
Metadata
- Authors
- Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-26
- Volume
- 22
- Issue
- 19
- Pages
- 10373
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3203918618
- Cited by
- 340
- References
- 248
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.